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Emulsified isoflurane is a new lipid emulsion forintravenous administration. Some investiga-tions demonstrate that the induction and main-
tenance of anaesthesia are possible with an intrave-
nous lipid emulsion of isoflurane.1,2  It is reported re-
cently that pretreatment of emulsified isoflurane has a
protective effect on myocardium against infarction fol-
lowingischemia-reperfusion(I/R),3,4 however, themecha-
nism remains unclear. This experiment aims to study
thepreconditioningeffect of emulsified isofluraneagainst
myocardial infarction and evaluate its mechanism on
the NO release and antioxidation action of myocardium.
METHODS
Animals
The investigation was approved by the Experiment
Committee of Wuhan University.All animals used were
cared for humanely and this conformed to the Guide for
the Institutional Animal Care and Use Committee of
Wuhan University. Male adult New Zealand white rab-
bits weighing 2.0-2.5 kg were used. The animals were
housed in a room with controlled temperature
(24°C±1°C)andhumidity (55%±5%)undera12-12hours’
light-dark cycle. They were allowed free access to food
and water.
Anesthesia and surgical preparation
Twenty-four male New Zealand white rabbits were
anesthetized with intravenous administration of sodium
pentobarbital (30 mg/kg) via the marginal ear vein and
maintained by 5 mg·kg-1·h-1 infusion. Body tempera-
ture was maintained at 38.5°C during the procedure
with a thermostatically controlled heating blanket. ECG
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Objective: To evaluate the protective effects of 8%
emulsified isoflurane after myocardial ischemia-reperfusion
injury and its mechanism in rabbits.
Methods: Twenty-four male adult New Zealand white
rabbits were anesthetized with intravenous injection of 30
mg/kg pentobarbital followed by 5 mg·kg-1·h-1 infusion. All
rabbits were subjected to 30 minutes of left anterior de-
scending coronary artery (LAD) occlusion and 3 hours of
subsequent reperfusion. Before LAD occlusion, the rabbits
were randomly allocated into three groups for precondi-
tioning treatment (eight for each group). The control group
(C group) received intravenously0.9% NaCl for 30 minutes.
The emulsified isoflurane group (EI group) received 8%
emulsified isoflurane intravenouslytill 0.64% end-tidal con-
centration for 30 minutes that was followed by a 15-minute
washout period. The Intralipid group (IN group) received
30% Intralipid for 30 minutes. The infarcted area, plasma
malondialdehyde (MDA) content, superoxide dismutase
activity (SOD) and nitrite concentration after 3-hour myo-
cardial perfusion were recorded simultaneously.
Results: For the myocardial ischemia-reperfusion in-
jury animals, the infarcted size in the EI group was signifi-
cantly reduced (91.9%±8%) as compared with control group
(39%±6%, t=5.19, P<0.01). The plasma SOD activity and
nitrite concentration in EI group were significantly higher
than thosein controlgroup (t=2.82, t=8.46, P<0.05), butMDA
content was lower in EI group than that in control group
(t=2.56, P<0.05).
Conclusions: The results indicate that emulsified
isoflurane has a cardioprotection effect against ischemia-
reperfusion injury. This beneficial effect of emulsified
isoflurane is probably through NO release and consequently
by increase in antioxidation of myocardium.
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leads were placed on the limbs. After a midline cervical
incision, a tracheotomy was performed, and the ani-
mals were intubated and ventilated with 100% oxygen
with the aid of a ventilator (Ohmeda-Excel 210 anes-
thesia apparatus, Philps M1026A monitor, tidal volume
15 ml/kg, respiratory rate 35 times per minute, end-
tidal CO2 partial pressure 30-35mmHg). The right femo-
ral artery was cannulated for blood sampling taken and
for measurement of meanarterial pressure (MAP).Heart
rate (HR) was determined from the arterial pressure
curve. The pericardium was incised and the heart was
exposed. A 2.0 silk suture was passed around the proxi-
mal part of the left anterior descending coronary artery
(LAD) and the ends of the silk suture were threaded
through a small vinyl tube to form a snare that could be
tightened to occlude and loosened to reperfuse the
artery. Myocardial ischemia was confirmedby ST-seg-
ment elevation on the ECG and regional cyanosis of
the myocardial surface. Reperfusion was confirmed by
myocardial blushover the risk area after the snare was
released. After 30 minutes of stabilization, the baseline
arterial blood pressure and heart rate were recorded.
Experimental protocol
After stable hemodynamic baselines were obtained,
all rabbits underwent 30 minutes of LAD occlusion and
3 hours of reperfusion. Before LAD occlusion for I/R,
the rabbits were randomly allocated into three groups
(eight foreach). The controlgroup (Cgroup) received0.9%
NaCl by a 5ml bolus intravenous injection and then
5 ml·kg-1·h-1 for 30 minutes. In the emulsified isoflurane
group (EI Group), 4 to 6 ml of 8% emulsified isoflurane
was administered intravenously at the rate of 1 ml/s
and thenmaintainedatanend-tidal concentrationof 0.64%
(corresponding to 0.5 minimal alveolar concentration4)
for 30 minutes by adjusting the rate of the microinfusion
pump at the rate of 4-6 ml·kg-1·h-1. The emulsified
isoflurane infusion was followed by a 15-minute wash-
out period. The Intralipid group (INGroup) received 30%
intralipid by a 5 ml bolus intravenous injection and then
5 ml·kg-1·h-1 for 30 minutes. 8% emulsified isoflurane
was provided by the Laboratory of Anesthesiology and
Critical Care Medicine, West China Hospital, Sichuan
University, China.
Sample collection
Samples(2 ml) of arterial blooddrawn from the femo-
ral artery catheter before ischemia at the end of 3 hours
of reperfusion were then collected in polyethylene tubes
containing 50 ml heparin (250 IU). The blood was im-
mediately centrifuged at 3 000 rpm for 15 minutes. The
plasma was recovered and aliquots were used for deter-
mination of malondialdehyde (MDA) content, superox-
ide dismutase (SOD) activity and nitrite concentration.
Measurement of myocardial infarction size
At the end of each experiment, myocardial infarc-
tion size was measured by the method of Tsai et al .5
At the end of the three hours reperfusion period, the
rabbits were sacrificed. Hearts, with intact occlusion,
were perfused (Langendorff technique) with Krebs solu-
tion at 37°C and 100 mmHg pressure for 5 minutes to
remove blood, and the coronary artery was briefly re-
occluded and 2.0 ml of Uniperse blue (1.0 mg/ml
Uniperse blue in Krebs solution) was then infused into
the jugular vein to delineate the area at risk (AAR). With
this technique, the previously non-ischemic area ap-
peared blue whereas theAAR remained unstained. The
AAR was cut out, weighed, and expressed as percent-
age of total ventricular weight. Then, the ventricular tis-
sue was sliced into 1 mm sections for incubation in
tetrazolium dye (2, 3, 5-triphenyltetrazolium chloride,
TTC, 1%, Sigma, USA) at 37°C in the dark for 30
minutes, followed by fixation with 10% formaldehyde in
salineat room temperatureovernight.The infarctedmyo-
cardium which was clearly visible by a lack of TTC stain-
ing within the AAR was carefully separated from the
non-infarcted myocardium. The non-infarcted and inf-
arcted myocardia were weighed separately.
Plasma MDA content, SOD activity and NO level
analysis
MDA content was determined by the thiobarbituric
acid method, whereas SOD activity was evaluated ac-
cording to thexanthine oxidase method. Theabsorbance
was measured at 532 nm and 550 nm for MDA content
andSODactivity, respectively,withaspectrophotometer.
MDA content and SOD activity were measured accord-
ing to the kit instructions (Jiancheng Biologic Project
Company, Nanjing, China). The commercially available
assay kit for measuring NO levels (expressed as the
nitrite concentration) was purchased from Jingmei
Biotech Co.Ltd Shenzhen, China. Each measurement
was performed in duplicate.
Statistical analysis
Data were expressed as mean±standard deviation
of mean.Analysisof variance (ANOVA) and theDunnett-
.  . Chinese Journal of Traumatology 2009; 12(1):18-21
t test were used for statistical analysis to compare the
values. Changes within and between groups were con-
sidered statistically significant when P<0.05.
RESULTS
Hemodynamic function
Thehemodynamic changesshowedno significant dif-
ferencesbetween groupsinMAP andHR (dataunshown).
Myocardial infarction size
Data for AAR and infarction size are presented in
Table 1. Mean left ventricular dry weight showed no sig-
nificant differences between groups. Emulsified
isoflurane significantly decreased the myocardial inf-
arction size to19%±8% in AAR as compared with the
control group (39% ± 6% of AAR, P=0.00). There were
nosignificant differencesbetweenC groupand INgroup.
Plasma MDA content, SOD activity and NO level
Plasma MDA content, SOD activity and NO level
are shown in Table 2. The plasma SOD activity and
nitrite concentration in EI group were significantly higher
than those in C group (P=0.02, P=0.00), but MDA con-
tent was lower in EI group than that in C group (P=0.04).
The above three parameters were not significantly dif-
ferent between C group and IN group.
DISCUSSION
Emulsified isoflurane (8%) is a new kind of fat emul-
sion preparation formulated as isoflurane in a lipid emul-
sion containing soybean oil, glycerol, and egg
phosphatide. Thecurrently marketed isoflurane, a clear,
colorless, and volatile liquid, is a widely-used volatile
anesthetic for general anesthesia. But intravenous ad-
ministrationof volatileanestheticshasmany advantages
over inhalational delivery such as more rapid induction
and recovery, easier control, and less cost because
theneedforanagentspecificvaporizerwouldbeeliminated.
Some investigationssuccessfully gaveemulsifiedvolatile
anesthetics in lipid to experimental animals.1, 2 Recently,
emulsified isoflurane pretreatment has been shown to
protect the myocardium against infarction following I/R.3,4
Our study also demonstrated that exposure of myocar-
dium to isoflurane (0.5 minimal alveolar concentration in
rabbits for 30 minutes) resulted in decreased infarcted
sizes following ischemia reperfusion. Furthermore, there
were nosignificant differencesbetween control group and
INgroup.Therefore,weconcludedthat thecardioprotective
effects of emulsified isoflurane were due to isoflurane
itself, not its vehicle — fat emulsion.
It is well known that oxygen free radicals, gener-
ated during I/R injury, contributes to the pathogenesis
of I/R injury and is also an important factor for the ar-
rhythmia induced by ischemia and reperfusion.6 Usu-
ally antioxidative ability of heart is evaluated by MDA
content and SOD activities. SOD is one of important
antioxidase that scavenges oxygen free radicals and
MDA is an end product of free radical chain reaction
and lipid peroxidation. Our present study showed that
Table 1. Weight and size of AAR
3.63±0.28
2.34±0.55
0.77±0.08
21±2
34±10
Items C group EI group t values  P values   IN group t values  P values
LV weight (g)
ARR(g)
Infarcted size (g)
Infarcted size/LV (%)
Infarcted size/ARR (%)
3.60±0.27
2.04±0.19
0.80±0.15
22±4
39±6
3.56±0.25
2.00±0.42
0.36±0.10**
10±3**
19±8**
Data are expressed with mean ± SD.LV = left ventricular; ARR = area at risk, **P< 0.01 compared with control group.
0.98
0.99
0.00
0.00
0.00
1.00
0.33
0.88
0.88
0.54
0.95
0.25
7.76
7.66
5.19
0.05
1.48
0.59
0.63
1.16
Table 2. Changes of MDA content, SOD activity and NO level 3 hours after reperfusion
Groups MDA (µmol/L) t values  P values SOD(U/mL)  t values  P values NO(µmol/L)  t values  P values
3.00±0.46
2.46±0.39*
3.08±0.38
76.79±8.12
66.99±6.53*
79.09±6.01
173.38±22.13
90.88±11.81**
171.75±23.09
Data are expressed with mean ± SD. *P< 0.05, **P< 0.01 compared with control group.
0.04
0.96
0.02
0.74
0.00
1.00
2.56
0.40
2.82
0.66
8.46
0.17
C
EI
IN
_ _ _ __ _
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emulsified isofluraneenhancedmyocardial antioxidative
ability, which might be one of mechanisms of cardiac
protection of emulsified isoflurane against I/R injury.
Our study demonstrated that pretreatment with
emulsified isoflurane increased NO level. Recent stud-
ies showed that NO acted as a trigger and as a media-
tor of the late phase of ischemic preconditioning against
cardiac dysfunction and infarction.7, 8 In addition, sev-
eral studies on myocytes in vitro and isolated rat hearts
in vivo indicate that the NO donor S-nitroso-N-acetyl-D,
L-penicillamin (SNAP) induces early protective effects
against I/R by preserving cell viability and improving
myocardial contractility.9, 10 Gourine et al11 reported that
a brief period of intracoronary administration of SNAP
before ischemia could decrease infarcted size, inhibit
neutrophil infiltration, and improve endothelial function.
Altogether these results suggest that NO exerts an early
ischemic preconditioning effect against myocardial I/R.
Our result also indicates that NO involves a crucial role
in emulsified isoflurane preconditioning.
There are reports that NO could maintain coronary
vasodilator tone, scavenge free radicals and exert
antioxidative activity.12,13 According to our experimental
results, we conclude that emulsified isoflurane protects
heart against I/R injury through increasing antioxidative
ability as a result of increasing NO production.
In summary, preconditioning with 8% emulsified
isoflurane may induce resistance against myocardial I/R
injury as evidenced by reduced myocardial infarction
size. This beneficial effect of emulsified isoflurane is
probably acting through NO release and consequently
by increase in antioxidation of myocardium.
REFERENCES
1. Zhou JX, Luo NF, Liang XM, et al. The efficacy and safety
of intravenous emulsified isoflurane in rats. Anesth Analg 2006;
102(1):129-134.
2. Yang XL, Ma HX, Yang ZB, et al. Comparison of minimum
alveolar concentration between intravenous isoflurane lipid emul-
sion and inhaled isoflurane in dogs. Anesthesiology 2006;104(3):
482-487.
3. Chiari PC, Pagel PS, Tanaka K, et al. Intravenous emulsified
halogenated anesthetics produce acute and delayed precondition-
ing against myocardial infarction in rabbits. Anesthesiology 2004
(5);101:1160-1166.
4. Rao Y, Wang YL, Zhang WS, et al. Emulsified isoflurane
produces cardiac protection after ischemia-reperfusion injury in
rabbits. Anesth Analg 2008; 106(5): 1353-1359.
5. Tsai SK, Lin SM, Huang CH, et al. Effect of desflurane-
induced preconditioning following ischemia-reperfusion on nitric
oxide release in rabbits. Life Sciences 2004;76(6): 651-660.
6. Jeroudi MO, Hartley CJ, Bolli R. Myocardial reperfusion
injury: role of oxygen radicals and potential therapy with
antioxidant. Am J Cardiol 1994; 73(6): B 2-7.
7. Wakeno-Takahashi M, Otani H, Nakao S, et al. Isoflurane
induces second window of preconditioning through upregulation
of inducible nitric oxide synthase in rat heart. Am J Physiol Heart
Circ Physiol 2005; 289(6): H2585-2591.
8. Chiari PC, Bienengraeber MW, Weihrauch D, et al. Role of
endothelial nitric oxide synthase as a trigger and mediator of
isoflurane-induced delayed preconditioning in rabbit myocardium.
Anesthesiology 2005; 103(1): 74-83.
9. Lochner A, Marais E, Genade S, et al. Nitric oxide: a trigger
for classic preconditioning? Am J Physiol Heart Circ Physiol 2000;
279(6): H2752-2765.
10. Rakhit RD, Edwards RJ, Mockridge JW, et al. Nitric ox-
ide-induced cardioprotection in cultured rat ventricular myocytes.
Am J Physiol Heart Circ Physiol 2000;278(4):H1211-1217.
11. Rakhit RD, Mojet MH, Marber MS, et al. Mitochondria
as targets for nitric oxide-induced protection during simulated is-
chemia and reoxygenation in isolated neonatal cardiomyocytes.
Circulation 2001;103(21):2617-2623.
12. Dawn B, Bolli R. Role of nitric oxide in myocardial
preconditioning. Ann NY Acad Sci 2002; 962: 18-41.
13. Schulz R, Kelm M, Heusch G. Nitric oxide in ischemia-
reperfusion injury. Cardiaovasc Res 2004; 61(3): 402-413.
  (Received May 15, 2008)
Edited by SONG Shuang-ming
